Day 2 of the DFSG 2024
Glad to be at the Diabetic Foot Study Group (DFSG) conference catching up with existing customers and to those new who have learnt the benefits of our SteriPlas Premium Cold Plasma. We look forward to the Kettering NHS presentation later today featuring the SteriPlas efficacy for chronic Diabetic Foot Ulcers.
SteriPlas combats Antimicrobial Resistance (AMR)
In 2016, the NHS identified the need to find clinically and cost-effective interventions for patients with diabetic foot disease as a high priority (College of Podiatry, 2019). This urgency is compounded by the rapidly rising incidence of antimicrobial resistance (AMR), a particular concern in people with DFU as infections are the leading cause of amputation (Hurlow et al 2018).
The SteriPlas has the ability to kill all forms of bacteria regardless if they are Gram-positive or Gram-negative or if they are protected within biofilm. It is a broad spectrum, topical antibacterial medical device that delivers consistent Premium Cold Plasma therapy directly at the site of infection. By eliminating bacteria that prevents the body from healing, it significantly reduces the antimicrobial resistance rates and prevents amputations from occurring.
Our proven clinical trials and studies have placed the SteriPlas as the leading Cold Plasma medical device in the market.
For more information about our strong clinical efficacy and #HealthEconomics, contact us at info@adtecplasma.com
SteriPlas proven to heal patients faster
“In cases with biofilm complications, CAP patients had an average wound area reduction of 44% whereas patients from the Control group had an average increase of 167%.”
Diabetic foot ulcers complicated with biofilm are already prone to poor arterial flow, therefore, the delivery of antibiotics to a complicated site already infected with multi-resistant bacteria may pose little to no help in healing the wound. This unfortunately can lead to amputations and further complications.
The SteriPlas benefits significantly to antibiotics due to its unfailing physical mode of action delivery during treatment. Multi-resistant bacteria, whether embedded and protected in biofilm, is quickly destroyed in as quick as 2 minutes. The treatment is delivered directly at the site of infection, is painless, contact-free, and most importantly has no side effects. As bacteria is destroyed so easily with our Premium Cold Plasma therapy, patients are healed and relieve the costs burden associated to hospitals.
“The SteriPlas is a cost and clinically effective treatment option for diabetic patients with infected chronic lower leg wounds in the absence of significant peripheral arterial disease.”
For more information about our strong clinical efficacy and #HealthEconomics, contact us at info@adtecplasma.com
SteriPlas proven to lower antibiotic usage
“Patients in the CAP treatment group were more likely to achieve reduction in wound size (71% vs 37.5%), resolution of wounds infection (71% vs 25%) and lower overall use of antibiotics (57% vs 100%).”
Our Health Economics data further demonstrates why the SteriPlas Premium Cold Plasma is the leading medical device for chronic diabetic foot ulcers. Continuing to relieve the cost burden associated to hospitals dealing with infection, the SteriPlas has been transforming how modern medicine works. Many users have changed their treatment guidelines to incorporate the SteriPlas and replace existing therapies that failed to work as well as the SteriPlas does.
For more information about our strong clinical efficacy and Health Economics, contact us at info@adtecplasma.com
Cheaper and Faster than Conventional Therapies
“The average cost of antibiotic treatment over the 6-month period was 192% higher for a control group patient (£683.64) than the average for a CAP patient (£234.03).”
The annual National Health Service (NHS) cost of wound management in the UK for 2017/18 was GB£8.3 billion. Of this, £5.6 billion was spent on managing unhealed wounds (Guest et al., 2020), including diabetic foot ulcers (DFUs) (Everett and Mathioudakis,2018). In 2014-2015 costs for ulceration and amputation in people with diabetes (PWD) was estimated at between £837 million and £962 million with more than 90% of expenditures related to ulceration (Kerr et al 2019).
In the USA, about 38 million Americans have diabetes, and each year a staggering 154,000 Americans will suffer amputations, roughly 80% of which will be the result of complications from diabetes. Their life expectancy following this procedure is five years.
Our mission has always been to revolutionise the global infection market. Bringing an innovative technology which aims to disrupt the conventional infection management market by delivering a more reliable, faster, and effective means of treatment. The SteriPlas has been doing exactly that since its launch many years ago and has expanded to cover the UK, EU and SE Asia with more plans to expand into new territories bringing the benefits to others who have yet to use our medical device.
For more information about our strong clinical efficacy and Health Economics, contact us at info@adtecplasma.com
Diabetic Foot Ulcer Health Economics
Adtec Healthcare Limited has invested over 10 years in clinical trials and studies to bring you over 80+ peer reviewed studies to validate why the SteriPlas Premium Cold Plasma is the leading medical device in the medical industry for chronic infection management. Not only is our medical device clearly proven to be the strongest against multi-resistant bacteria protected within biofilm but it can treat a wide variety of deep and hard to reach areas that are often recalcitrant to conventional therapies, therefore not limited to superficial wound treatments.
Our recent goal has been to collect the cost effectiveness findings to demonstrate just how the cost burden can be eliminated by the hospital when using our SteriPlas. In the case of chronic diabetic foot ulcers with biofilm presence in the NHS, the SteriPlas has been shown to reduce antibiotic usage by 57% for patients thus relieving the ongoing costs thrown onto the hospital service. Not only are patients healed significantly faster, bed occupancy significantly reduced, and limbs are saved but there is a significant reduction in patient visits to the hospitals thus relieving further costs associated to the hospital.
For more information about our Health Economics data, contact us at info@adtecplasma.com
SteriPlas to be presented at the DFSG conference
Adtec looks forward to supporting Ms Jemma Cruickshank, Antimicrobial Pharmacy Technician from Kettering General Hospital NHS Foundation Trust, at the Diabetic Foot Study Group (DFSG) conference in September.
Jemma has been invited to present the “Retrospective review of the use of argon cold plasma therapy in non-healing diabetic foot ulcers over a 3-year period within a DGH Diabetic Foot MDT Service” at the conference.
Her presentation will include the strong benefits of the SteriPlas on chronic and large diabetic foot ulcers prone to biofilm infections.
The abstract for this presentation can be found here: https://distribute.m-anage.com/from.storage?image=erIsXlaDuNOv64Tv4JyKY6XW3cI1HigkZNgT5cOgYv7Vzt_UHvGbDPesijzVroVO0
For more information about our SteriPlas Premium Cold Plasma medical device, send us an email info@adtecplasma.com
What makes our SteriPlas safe and effective?
What makes our SteriPlas Premium Cold Plasma safe and effective?
Adtec has been the global leader of Cold Plasma medicine, having developed Cold Plasma products for over 20 years and being the first company worldwide to conduct clinical trials on wounds. In total, Adtec boasts over 80+ clinical trials and studies with no side effects reported.
Whilst there are many forms of Cold Plasmas on the market, our SteriPlas Cold Plasma is dense and slowly propelled towards the treatment site enabling bacterial destruction in deep and hard to reach infection areas. The argon Cold Plasma is microwave, 2.45GHz generated using crucial components within the body of the medical device. This is why it is larger in size but at the advantage of delivering reliable and consistent results and easily tackles complicated biofilm issues within chronic infections unlike the other variations of Cold Plasma on the market. This is also why our clinical evidence is often cited by other Cold Plasma manufacturers as our promising results far outweigh the results achieved by Cold Plasma devices with different plasma designs.
To learn more about our strengths and benefits, contact us at info@adtecplasma.com
Leading the way in Cold Plasma Medicine
The antibiofilm properties of the SteriPlas has been widely documented across our 80+ clinical trials and studies. It is being widely used to treat a multitude of infection conditions such as Diabetic Foot Ulcers, Sternal Wounds and LVAD infections in the UK, EU and SE Asia. Helping to significantly reduce morbidity, mortality, amputation and bed occupancy rates, the SteriPlas has been transforming modern medicine by simplifying and accelerating the way these chronic and non-healing wounds are treated. We have also documented the significant cost saving benefits of using the SteriPlas Premium Cold Plasma all with the added benefit of no side effects due to its safe, microwave 2.45GHz argon plasma generation.
To learn more about the benefits we can bring you, contact us at info@adtecplasma.com